Loading data for NTLA — first visit, this takes a few seconds.
Intellia Therapeutics, Inc. (NTLA)
NasdaqGM: NTLA
· Real-Time Price · USD
12.50
-0.19 (-1.50%)
At close: Sep 02, 2026, 1:40 PM
The price, the headline numbers and the latest news, in one place.
Intellia Therapeutics, Inc. (NTLA) Stock Price, Analysis & Data
-1.46% (1D)
| Bid | 8.2 |
| Market Cap | 1.76B |
| Revenue (ttm) | 59.5M |
| Net Income (ttm) | -400M |
| 1.79 | |
| -3.34 | |
| n/a | |
| -4.84 | |
| P/B (ttm) | 2.42 |
| P/S (ttm) | 29.65 |
| Earnings Date | Nov 5, 2026 |
| Ask | 13.92 |
| Volume | 1,930,379 |
| Avg. Volume (20D) | 4,778,326 |
| Open | 12.67 |
| Previous Close | 12.69 |
| Day's Range | 12.28 - 13.13 |
| 52-Week Range | 7.95 - 28.25 |
| Analyst | n/a |
| Price Target | n/a |
| Dividends | n/a |
| Ex-Dividend Date | n/a |
About NTLA
Intellia Therapeutics, Inc. operates as a clinical-stage genome editing company focused on developing potentially curative therapeutics using CRISPR/Cas9-based technologies. The company offers clustered, regularly interspaced short palindromic repeats (CRISPR)/CRISPR associated 9 (Cas9) technology for genome editing. The company provides a modular platform, to advance in vivo and ex vivo therapies for diseases. The company's in vivo product c...
Industry Biotechnology
Sector Healthcare
IPO Date May 6, 2016
Employees 377
Stock Exchange NasdaqGM
Ticker Symbol NTLA
Website https://www.intelliatx.com
Financial Performance
In 2025, Intellia Therapeutics's revenue was 67.67M, an increase of 16.92% compared to the previous year's 57.88M. Earnings were -412.69M, a decrease of -20.49%.
Financial StatementsEarnings Surprise
Intellia Therapeutics has released their quarterly earnings on Aug 6, 2026:
- Revenue of $7.66M misses estimates by $0, with -46.23% YoY decline.
- EPS of -0.8 misses estimates by -0.02, with 18.37% YoY growth.
Intellia Therapeutics, Inc. is scheduled to release its earnings on Nov 5, 2026, before market opens.
Analysts project revenue of ... Upgrade
Analysts project revenue of ... Upgrade
Page 1 of 2